2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 1,601–1,700 of 2,029
Hwang, Y., Heo, S., An, J., Na, S. K., Kim, S., Song, I. H., Nault, J., Song, G.-W., Choi, S. H., & Shim, J. H. (2026) · Liver Cancer · doi:10.1159/000551666
“Type 2 diabetes mellitus was defined as an HbA1c level of ≥ 6.5%, a fasting glucose level of ≥ 126 mg/dL, or the current use of anti-diabetic medications [22].”
InfluentialEl-Nagar, G. F., Khoder, S. A.-E.-K., Gawaly, A. M., et al. (2026) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_94_25
He, X., Ma, D.-H., Liu, Z., Guo, Y.-F., Zhao, R., Sun, P.-P., & Zhong, X.-L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1798687 · Cited by 2
“In accordance with the criteria established by the American Diabetes Association (33)”
Ma, C., Li, J., Yu, R., Li, J., Liang, Z., Wang, K., Feng, H., Liu, P., Wang, X., & Weng, Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02936-z
“Diabetes was defined according to the American Diabetes Association criteria [24]: HbA1c ≥ 6.5%, FBG ≥ 7.0 mmol/L (126 mg/dL), or self-reported diabetes/insulin use.”
InfluentialFogaça, A. L., Ostolin, T. L. V. D. P., Pagano, R., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1775650
Kim, S. S., Park, S., Kim, J., Park, H. J., Ryang, S., Im, M., Kim, D., & Lee, K. (2026) · Diagnostics · doi:10.3390/diagnostics16070992
“…(7.0 mmol/L); (2) Hemoglobin A1c (HbA1c) ≥ 6.5%; (3) 2 h Plasma Glucose (2h-PG) ≥ 200 mg/dL (11.1 mmol/L) during a 75g Oral Glucose Tolerance Test (OGTT); or (4) current treatment with insulin or oral antidiabetic drugs, as referenced by the 2024 American Diabetes Association (ADA) standards [12].”
InfluentialCai, Y., & Guo-xin, Z. (2026) · Medicine · doi:10.1097/md.0000000000048214
“[24] Cancer history was self-reported.”
Zhao, R., Feng, X., Wang, N., Wang, Z., Liu, J., & Wang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783770
Li, M., Hu, H., Liu, Y., Wu, X., Zhang, Y., Li, Y., Yang, F., Li, Y., & Lin, S. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1794931
“Glucose tolerance status was de fi ned using American Diabetes Association criteria (Committee, 2023): DM as fasting plasma glucose (FPG) ≥ 7.0 mmol/L or 2-hour plasma glucose (2h-PG) ≥ 11.1 mmol/L; pre-DM as impaired fasting glucose (FPG 5.6 – 6.9 mmol/L) and/or impaired glucose tolerance (2h-PG…”
InfluentialLiu, L., Alifu, J., Mohammed, A.-Q., Yin, G., Abdu, F. A., & Che, W. (2026) · Mediators of Inflammation · doi:10.1155/mi/6052273
Mwakyula, I. H., Mbwile, G. R., & Nassoro, D. D. (2026) · Clinical Case Reports · doi:10.1002/ccr3.72430
Determinants of self-monitoring adherence in type 2 diabetes: bridging the gap in patient care
Hyassat, D., Alonezat, K., Abdalrahim, M. S., Batieha, A. M., Khader, Y. S., Alnsour, S., Al-Qalalweh, S. B., & Ajlouni, K. M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1784888
“…(ADA) criteria, defined as an HbA1c level ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), 2-h plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test, or a random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in the presence of classic symptoms of hyperglycemia (18).”
InfluentialPark, S. K., Chung, Y., Oh, C., Ryoo, J., & Jung, J. Y. (2026) · Yonsei Medical Journal · doi:10.3349/ymj.2025.0330
Coleman, N., Khoylyan, A., Parry, M. W., Tang, A., & Chen, T. (2026) · Cureus · doi:10.7759/cureus.106232
“Patients were divided into non-diabetic and diabetic cohorts based on preoperative HbA1c levels of 6.5% or ≥6.5%, as defined by the American Diabetes Association, obtained within two weeks before surgery [33].”
InfluentialAbdi, R. M. A., Saadeh, N. A., Hijazi, H. H. A., Al-Zoubi, N. A., Marone, A., Maheshwari, N., & Hielscher, A. H. (2026) · BioMedical Engineering OnLine · doi:10.1186/s12938-026-01564-z
“Type 2 diabetes was defined according to American Diabetes Association Standards 2024 criteria as having a fasting glucose ≥ 126 mg/dL, HbA1c ≥ 6.5%, or random glucose ≥ 200 mg/dL with symptoms of hyperglycemia [35].”
InfluentialQu, M., Qu, Y., Luo, Y., & Huang, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-47269-0
“Diabetes mellitus was defined as FPG ≥ 7.0 mmol/L, glycated hemoglobin (A1C) ≥ 6.5%, a documented history of diabetes, or current use of antidiabetic agents 45 .”
InfluentialHe, Z., Xiong, W., Li, Y., Wu, X., Zhang, Y., Shan, X., Liu, Y., & Rang, W. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100779
“Diabetes mellitus was defined by self-reported physician diagnosis, use of oral hypoglycemic agents or insulin, fasting blood glucose level > 126 mg/ dL, oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L, or hemoglobin A1c (HbA1c) ≥ 6.5% [24].”
InfluentialAdawadkar, N., Pandey, D., & Sinha, U. (2026) · Cureus · doi:10.7759/cureus.106459
Peled, T., Ben-Ami, T., Helman, S., Lando, M. B., Grisaru‐Granovsky, S., & Rottenstreich, M. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70998
Sound of Aging: Large-Scale Evidence for a Voice-Based Biological ClockPreprint
Krongauz, D. L., Marmor, Y., Zulti, A., et al. (2026) · medRxiv · doi:10.64898/2026.04.05.26350190
Yang, J., Li, X., & Qi, F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04799-1 · Cited by 1
“Diabetes was ascertained through any of the following: self-reported physician diagnosis, HbA1c ≥ 6.5%, fasting glucose ≥ 7.0 mmol/L, glucose-lowering medication, or insulin therapy [23].”
InfluentialMiller, A., Coleman, C. D., Kiel, J., Beavers, K. M., & Jonnalagadda, S. S. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100265
Chau, L. B., Tri, D. V., Quy, V. T., Tiwari, R., Phan, Q., Kieu, T. T. M., Tho, D. V., Khoi, L. M., Quỳnh, N. T. N., Abdullah, R. M., et al. (2026) · Tropical Medicine and Health · doi:10.1186/s41182-026-00943-5
“All diagnoses were made according to the criteria issued by the Vietnam Ministry of Health [11] which are consistent with those recommended by the American Diabetes Association [12].”
Singh, G., Dholariya, S. J., Kaliya, M., Modi, A., Sonagra, A. D., & Parchwani, D. N. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2657057
“Diabetes was diagnosed according to the American Diabetes Association (ADA) criteria [16].”
Husna, C., ., D., Firdausa, S., et al. (2026) · The Open Nursing Journal · doi:10.2174/0118744346456899260403115613
Demir, S. Ç., Batman, A., YAZICI, D., Deyneli, O., & Peker, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082901
“Despite its clinical significance, a substantial proportion of individuals with moderate-to-severe OSA remain undiagnosed [7].”
IL-1β/IL-1Ra ratio dysregulation in islet autoantibody–positive adult-onset diabetes
Tleumagambetova, B., Kudabayeva, K. I., Bazargaliyev, Y., & Vudu, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784582 · Cited by 1
Giannopoulou, E., Moawia, A., Högel, J., Lerner, J., Zorn, S., Denzer, C., Siebert, R., & Wabitsch, M. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-026-00229-0
Pan, J., Chen, F., Liao, W., Ye, W., Chen, B., Lu, T., Li, K., Liu, F., Deng, X., Sun, T., et al. (2026) · International Journal of COPD · doi:10.2147/copd.s590822
Association between HbA1c and clinical outcomes of coronary artery bypass grafting “about”
Ayten, S. (2026) · Pamukkale Medical Journal · doi:10.31362/patd.1873950
ELSNER, P., NEYER, M., Vogel, J. B., SCHNETZER, L., Drexel, H., Saely, C. H., & Festa, A. (2026) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-026-01143-w
Fan, J., Zuo, L., Du, P., Tian, R., Zhao, W., Li, J. S., Liu, Y., & 于德新 (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02691-8
“…mmol/L, 2-h glucose ≥ 11.1 mmol/L during a 75-g oral glucose tolerance test, or random plasma glucose ≥ 11.1 mmol/L in an individual with classic symp - toms of hyperglycaemia or hyperglycaemic crisis [15]; (b) abdominal CT performed within 3 months; (c) CT image quality sufficient for analysis.”
InfluentialSourij, C., Müller, A., Al-Baghdadi, A., Aziz, F., Tripolt, N. J., Pferschy, P. N., Andritz, E., Kojzar, H., Stadlbauer, V., Garcia, S. L., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70328
Ewers, B., Davidsen, E., Hansen, M. J., & Nielsen, K. K. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09055-8
Hu, X., Yang, X., Zhu, Z., Yang, Z., Wang, P., Wu, M., & Zhang, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1768784
Pallotta, D. P., Tovoli, F., Barbaro, E., Sinno, A. D., Chiorat, M. C. A., Santangeli, E., & Piscaglia, F. (2026) · Livers · doi:10.3390/livers6020032
“Low bone mass density occurs in AIH patients more commonly than in the general population, with retrospective series reporting a prevalence of 15% and 43% for osteoporosis and osteopenia respectively [134].”
Ge, X., Luo, Z., Zhang, Y., Zhang, L., Wang, G., Yuan, X., Li, Q., & Zhai, X. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1744208
Alotaibi, A. A., Alqarni, A. S., Alharbi, G. A., et al. (2026) · Cureus · doi:10.7759/cureus.107235
Tripathi, P., KADAM, N. S., Kathrikolly, T., & GANLA, M. H. (2026) · Cureus · doi:10.7759/cureus.107273
Ren, H., Xiao, Y., Tang, Z., Shi, Y., Zeng, Z., Tang, B., He, X., & Xiao, R. (2026) · Dermatologic Therapy · doi:10.1155/dth/8727416
Labile Hemoglobin A1c (LHbA1c): From analytical interference to clinically valuable biomarker
Wang, K., & Han, W. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121018 · Cited by 1
Liu, H., Zhang, Y., Feng, L., Zhang, J., Sun, Y., Zhao, Y., Jiang, M., Liu, X., Tracey, G. J., Chen, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71798-x
Kuang, Y., Yu, Y., Li, J., Peng, C., Ji, Y., Tian, J., Chen, S., Wang, J., & Feng, L. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03461-w
“According to the American Diabetes Association (2024) diabetes diagnostic criteria [28], DM was defined as an fasting plasma glucose (FPG) ≥7.0 mmol/L or glycated hemoglobin (HbA1c) ≥6.5%.”
InfluentialKloura, C., Jensen, M. M., Ekblond, T. S., Pedersen, H., Raben, A., Clemmensen, K. K. B., Færch, K., Blond, M. B., & Quist, J. S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113276 · Cited by 1
Liu, J. N., Qiu, S., Tang, J., Guo, X., & Sun, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1809438
Wu, L., Na, R., & Qiu, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1822839
Riquelme-Hernández, C., Reyes-Barría, J. P., Mancilla, C. S., Cavero‐Redondo, I., Vásquez-Carrasco, E., Sepúlveda, P., Sandoval-Vásquez, C., & Cigarroa, I. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1806558
Leow, A. S., Ong, J. Y.-S., Thong, E. H., Seah, A. W.-J., Ho, A. K. H., Tan, E., Quek, S., Kong, W.-F., Yeo, T., Sia, C., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1767022
Josefson, J. L., Gregg, B. E., Sen, S., Rajakumar, K., McGowan, E. C., Andrei, A., Arend, A. B., Rick, A.-M., Marshall, E., Caal, K., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116936
“10 Furthermore, few pre-birth cohorts with longitudinal HM profiling and later maternal-child outcome ascertainment exist given the costs and multi-disciplinary approach required to investigate health across obstetric, paediatric and endocrine perspectives.”
García-Benito, C., Oxley-Babsky, L., Crespo-Martín, M., del-Molino-Serrano, E., Santos-Villanueva, R., Olloqui-Fuentes, A., Guillén-Lorenzo, L., & García-Rio, F. (2026) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-026-00516-3
Kwon, Y.-J., Song, Y., Lee, J.-W., Heo, S.-J., & Lee, J. E. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113284
Lin, Z., Song, Y., Yuan, S., Li, B., He, J., & Dou, K. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03196-y
“Individuals with a history of diabetes, receiving glucose-lowering treatment, or demonstrating an FBG ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, or 2-hour plasma glucose ≥ 11.1 mmol/L during an oral glucose tolerance test were categorized as having diabetes [25].”
InfluentialDahl, M., Høgh, A. L., Refsgaard, J. C., Bredsgaard, M., Moeslund, N.-J., Svenstrup, D., Kinnerup, M. B., Mejldal, A., & Lindholt, J. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag309 · Cited by 1
Li, D., He, J., Xie, W., Yang, J., Wang, L., Zhao, D. D., Zhang, N., & Duan, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1769975
Ha, J., Hwang, H. B., Kim, H., Lee, S. W., Lee, J., Park, J. H., Lee, J., & Kim, I. Y. (2026) · Biosensors · doi:10.3390/bios16050251
“Healthy subjects had HbA1c < 5.7%, pre-diabetic participant 5.7–6.4%, and participants with diabetes > 6.4% [37].”
InfluentialXu, W., Zhang, Q., Hong, Y., & Mao, Z. (2026) · Medical Devices Evidence and Research · doi:10.2147/mder.s568279
“Effective blood glucose control can significantly reduce serious complications of diabetes, such as retinopathy, peripheral neuropathy, and cardiovascular and cerebrovascular diseases 20.”
Yao, X., Huang, D., Shi, X., Xiang, F., & Liu, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1818019
Abbas, K. M., Mohammed, M. S. A., & Hamas, M. A. A. (2026) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v10i2.2721
“Patients with diabetes mellitus were classified according to the American Diabetes Association (ADA) criteria and further divided into controlled and uncontrolled diabetes mellitus (DM) subgroups, based on treatment type and disease duration [18,19].”
wang, F., Yu, D., & Bai, G. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01660-9
Yanovskaya, E. A., & Яновская, М. Е. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-1-05
Diabetes and cancer: clinical implications for integrated metabolic–oncologic care
Fuchs-Tarlovsky, V. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1824109
Cinque, F., Liparoti, A., Varchetta, S., Bozzi, G., Castelli, V., Ludovisi, S., Muscatello, A., Trombetta, E., Tornese, M., Mariani, B., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03540-4
Xu, X., He, M., Wang, N., Liu, X., Wei, M., Jiang, Y., Peng, Q., Shi, J., He, D., & Zhao, G. (2026) · Nutrients · doi:10.3390/nu18091355
Elkhider, O., Elshaikh, O., & Sharma, A. (2026) · Cureus · doi:10.7759/cureus.108291
Rohilla, L., Walia, P., Sahni, N., & Dayal, D. (2026) · International Journal of Clinical Nursing Research Society · doi:10.5005/ijcnrs-11024-0008
Qin, S., Li, N., Zhou, Y., Zhang, Y., Yu, Z., Liu, X., Zhong, J., Liu, C., Zhang, P., Pei, C., et al. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s589653
Precision Medicine in Diabetes Phenotypes
Pillai, S. S., Mozumdar, K., & Ashraf, A. P. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_13
Liu, Y., Meng, Y., Duan, R., et al. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8611325
Sheng, L., Li, X., Yu, J., Yang, X., Li, H., & Xu, H. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s588573
do Nascimento, R. M., Santos, A., Guadagnini, D., de Santana, L. S., Junior, A. C. S., Passone, C., Bezerra, M. G. T., Gomes, L. G., Corrêa‐Giannella, M. L., Nery, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1716020
Phonyiam, R., Neelapaichit, N., Srichalerm, T., & Teng, C. (2016) · JBI Evidence Synthesis · doi:10.11124/jbies-25-00357
Ye, M., Wu, H., Shan, F., Zhou, H., Yu, J., Wu, Y., & Hao, T. (2026) · Gynecological Endocrinology · doi:10.1080/09513590.2026.2668870
Çelebi, M., Sarıtop, S., Yılmazoğlu, E., et al. (2026) · Materials Science in Semiconductor Processing · doi:10.1016/j.mssp.2026.110776
Dhotre, S. V., Dhotre, P. S., Rao, A., & Nagoba, B. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i5.118333
Nas, N., & Sağlam, F. (2026) · Healthcare · doi:10.3390/healthcare14101274
“The average HbA1c levels were calculated to assess long-term and short-term glycemic control, which is a widely accepted marker for diabetes management and treatment outcomes [9].”
Machine learning-based prediction of diabetic retinopathy using clinlabomics: a multi-center study
He, L., Zhang, M., Wang, X., Wang, T., & Wang, P. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03524-y · Cited by 3
“…people with diabetes commonly undergo routine laboratory testing (hematologic, biochemical and urinalysis panels) as part of standard care; these data capture systemic states (metabolic con-trol, inflammation, coagulation and more) that are plausibly linked to retinal microvascular injury [18].”
Guo, C., Yang, W., Xue, R., Zhou, Q., Liang, Y., & Zhang, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s600905
Leng, M., Tang, S., Gan, C., Xu, J., & Luo, D. (2026) · Journal of Medical Systems · doi:10.1007/s10916-026-02403-3 · Cited by 1
“…for inclusion if they satisfied the following criteria: (1) patients with T2DM, diagnosed according to internationally recognized criteria [ 23] The exclusion criteria were as follows: (1) studies that were reviews, letters, commentaries, conference abstracts, academic dissertations, study…”
徐, 郝. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1651864
A review of autophagy in the pancreas: normal physiology and pathophysiology
Piper, M., & Kinsey, C. G. (2026) · Autophagy Reports · doi:10.1080/27694127.2026.2665907
“The two most prevalent forms of DM are type 1 diabetes mellitus (T1DM), characterized by insufficient insulin production due to autoimmune β-cell destruction, and type 2 diabetes mellitus (T2DM), characterized by insulin resistance and β-cell dysfunction [60,61].”
Adejumo, B. I. G., Obiajunwa, A., Uyi, A., Olise, N. A., Oyakhire, F. O., Obasuyi, G. E., Usman-Onoruvie, V., Fajemidagba, G. A., Aiyesoro, F. O., Adegboye, A. A., et al. (2026) · Discover Public Health · doi:10.1186/s12982-026-02043-5
“Recent clinical guidelines further emphasise that prediabetes is not merely a transient state but a clinically actionable condition requiring early identification and intervention to prevent progression to T2DM [3, 4].”
Zong, W., Yu, J., Zhang, Q. Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70875
Lule, N. O., Lule, K. O., Özsoy, Ö., & Yıldız, H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103734
“%) according to current diagnostic standards [25].”
InfluentialValidated prediction model for in hospital mortality in AECOPD with type 2 diabetes
Chen, J. M., Zhang, X., Liu, K., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-50581-4
“000) 11 ; (4) diagnosis of T2DM based on a documented physician diagnosis and/or long-term use of glucose-lowering therapy, or fulfillment of the American Diabetes Association (ADA) 2024 diagnostic criteria 12 .”
Sağlar, Y., Durmus, H., Eren, F. K., Erişmiş, B., & Şahiner, E. S. (2026) · Research Square · doi:10.21203/rs.3.rs-9396849/v1
Lin, R., Jiang, W., Wang, D., Xu, L., & Du, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1784292 · Cited by 1
“Prediabetes was defined using fasting glucose and HbA1c levels; without an oral glucose tolerance test, we could not evaluate impaired glucose tolerance, and some cases may have been missed (38).”
David, D. T., Wasnyo, Y. F., Ndenane, N., Sobngwi-Tambekou, J. L., Philomène, M. M., & Sobngwi, E. (2026) · Pan African Medical Journal · doi:10.11604/pamj.2026.53.41.49576
Medina, M., Cureau, F. V., Schaan, B. D., et al. (2026) · Nutrition · doi:10.1016/j.nut.2026.113267
Xu, Z., Zhang, Y., & Zhang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1850071
Sun, Y., Cao, H., Zhao, M., Pang, Y., Zhang, Y., Gao, R., Wang, F., & Liu, S. (2026) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2026.101024
Lee, E. J., Lee, G. B., Her, Y. S., Shin, K. E., Cho, K.-H., Han, K., Chang, N.-W., Lee, Y., Han, B., & Kim, Y. (2026) · Clinical and Experimental Dental Research · doi:10.1002/cre2.70371
“Type 2 diabetes (T2DM), characterized by insulin resistance, accounts for 90%–95% of all diabetes (American Diabetes Association Professional Practice Committee 2024).”
InfluentialOmeje, I. J., Takai, I. U., ATANDA, A., Ismail, A., Abdurrahman, A., NTOIMO, L. F. C., & Ifanayajo, O. O. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09267-y · Cited by 1
Zhao, S., Tang, L., Xiong, N., Liang, L., Wu, X., Yu, C., Wei, X., Wu, X., & Dai, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1788311
Beyond A 1c : a narrative review of mental health integration in pediatric type 1 diabetes care
Jetter, E. M., Eason, A., Waldmann, T., & Carr, B. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0005
“Type 1 diabetes (T1D) is an autoimmune condition characterized by immune-mediated destruction of pancreatic β -cells and absolute insulin de fi ciency [1].”
Xue, X., Liu, L., Tan, Z., Zhou, L., Li, S., Yan, W., Liu, X., Ye, M., Li, X., & Ren, H. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1800772
Diagnostic Performance of Triglyceride–Glucose (TyG) Index for Type 2 Diabetes in Bangladeshi Adults
Dutta, K. K., Bhowmick, A., Hossain, R., et al. (2026) · Journal of Medicinal Chemistry and Therapeutics · doi:10.71193/jmct.20260011
HealthMarkers: Clinical and Metabolic Biomarker Calculation Toolkit
Suleman, S. (2026) · CRAN: Contributed Packages · doi:10.32614/cran.package.healthmarkers
Jang, K. (2026) · Health & Social Care in the Community · doi:10.1155/hsc/5145474
Soliman, A. M., Mohammed, A., Rakha, N. K., Abdelgawad, E. M., Attia, A., & Ahmed, R. M. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04959-1
“[29].”
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.